Molecular Formula | C40H76N2O12 |
Molar Mass | 777.05 |
Density | 1.16±0.1 g/cm3(Predicted) |
Melting Point | >118°C (dec.) |
Boling Point | 833.0±65.0 °C(Predicted) |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | White to Pale Yellow |
pKa | 13.42±0.70(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
Stability | Hygroscopic |
In vitro study | The MIC values in serum are significantly lower than those in artificial medium; at an initial inoculum size of 10 6 cfu/mL, these are 64-, 8- and 64-fold lower for gamithromycin, tylosin and tilmicosin, respectively, against MmmSC strain B237 in serum compare to artificial medium. A similar pattern emerges for Tan8. Heat-inactivation of serum results in an MIC for gamithromycin that is higher than in either non-treated serum or artificial medium. |
In vivo study | The proportion of foals that recover without the need for a change in treatment is significantly (P<0.048) higher for foals treated with Gamithromycin (GAM) (38 of 40; 95%) or AZM-RIF (39 of 40; 98%) compare to control foals (32 of 41; 78%). The clinical scores, number of abscesses and the abscess scores after 1 and 2 weeks of treatment are significantly lower for foals treated with Gamithromycin (GAM) or AZM-RIF compare to control foals. The WBC count of foals treated with Gamithromycin (GAM) is significantly higher than that of foals treated with AZM-RIF on week 3 of treatment. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.287 ml | 6.435 ml | 12.869 ml |
5 mM | 0.257 ml | 1.287 ml | 2.574 ml |
10 mM | 0.129 ml | 0.643 ml | 1.287 ml |
5 mM | 0.026 ml | 0.129 ml | 0.257 ml |